Chroniject™ Technology

Oakwood Laboratories, L.L.C., is an emerging specialty pharmaceutical company focused on advanced injectable drug delivery. Its primary technology platform, CHRONIJECT™, is a sustained release microsphere formulation that enables a single injection to deliver drug for periods ranging from one week up to one year. Oakwood is currently using this patented technology to develop a portfolio of proprietary products in a variety of therapeutic areas, including oncology, endocrinology, CNS, and dermatology. Oakwood also partners with pharmaceutical and biotechnology companies to apply its drug delivery technology to new chemical entities or to extend the patent life of existing products. The company has recently completed an aseptic manufacturing facility for the production of clinical and commercial supplies of products employing CHRONIJECT™ technology, as well as other liquid and lyophilized parenteral pharmaceuticals for contract customers.

What is Chroniject™?

CHRONIJECT™ is a pharmaceutical manufacturing process capable of producing sterile microspheres for
sustained release drug delivery in unit dose lyophilized vials.

Advantages of Chroniject™

• Reduced number of injections
• Enhanced patient compliance
• Wide range of delivery duration
• Suitability for wide variety of ADS
• Proven safety of polymer
• Ease of scalability

• Simple, portable process
• Validatable process
• Lot-to-Lot consistency
• Product stability
• Easy reconstitution with WFI
• Suspendability and syringeability of dosages
• Patented process